Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31561697 | 0.84 | L3MBTL1 (0.45) | L3MBTL1MAPK1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL7050570 | 0.84 | L3MBTL1 (0.45) | L3MBTL1MAPK1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL15559998 | 0.82 | CXCL8 (0.44) | L3MBTL1MAPK1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL11273707 | 0.80 | L3MBTL1 (0.45) | L3MBTL1MAPK1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL26661047 | 0.77 | GAA (0.50) | L3MBTL1MAPK1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL16811764 | 0.76 | LMNA (0.40) | L3MBTL1MAPK1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL536175 | 0.75 | TSHR (0.46) | L3MBTL1MAPK1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL343227 | 0.75 | TSHR (0.46) | L3MBTL1MAPK1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL8390663 | 0.75 | TSHR (0.46) | L3MBTL1MAPK1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL29835035 | 0.74 | TSHR (0.50) | L3MBTL1MAPK1SMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559716-B1 | PYRAZOLONAPHTHYRIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | KANAZAWA HASHIME | 2010-04-15 | — | — | US | disclosed |
| CN-100572381-C | Pyrazolonaphthyridine derivative | ASKA PHARM CO LTD (JP) | 2009-12-23 | — | — | CN | disclosed |
| US-7608716-B2 | Pyrazolonaphthyridine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20060040972-A1 | Pyrazolonaphthyridine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| CN-1717409-A | Pyrazolonaphthyridine derivative | GRELAN PHARMACEUTICAL CO (JP) | 2006-01-04 | — | — | CN | disclosed |
| EP-1559716-A1 | PYRAZOLONAPHTHYRIDINE DERIVATIVE | Grelan Pharmaceutical Co., Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040972-A1 | Pyrazolonaphthyridine derivative | PDE3B, PDE3A, PDE4A | L3MBTL1 3564/4885MAPK1 561/4885SMN1; SMN2 3740/4885 |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | PDE3B, PDE3A, PDE4A | L3MBTL1 3594/4885MAPK1 560/4885SMN1; SMN2 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.